These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30699280)

  • 21. HCV management in resource-constrained countries.
    Lim SG
    Hepatol Int; 2017 May; 11(3):245-254. PubMed ID: 28224352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Betrixaban, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir.
    Hussar DA; Inman B
    J Am Pharm Assoc (2003); 2017; 57(6):750-754. PubMed ID: 29092766
    [No Abstract]   [Full Text] [Related]  

  • 23. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
    Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Hepatitis C Virus: An Update on Medications and Patient Education.
    Molino S; Cottreau J
    Orthop Nurs; 2019; 38(4):273-277. PubMed ID: 31343633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Pawlotsky JM
    Semin Liver Dis; 2019 Jul; 39(3):354-368. PubMed ID: 31041789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
    Pearlman B; Perrys M; Hinds A
    Am J Gastroenterol; 2019 Sep; 114(9):1550-1552. PubMed ID: 31082871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
    Vermehren J; Serfert Y; Cornberg M; Stoehr A; Klinker H; Simon KG; Teuber G; Deterding K; Schulze Zur Wiesch J; Jung MC; Manns MP; Zeuzem S; Wedemeyer H; Sarrazin C
    Z Gastroenterol; 2020 Sep; 58(9):841-846. PubMed ID: 32947629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
    Brieva T; Rivero A; Rivero-Juarez A
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
    Maughan A; Sadigh K; Angulo-Diaz V; Mandimika C; Villanueva M; Lim JK; Ogbuagu O
    BMC Infect Dis; 2019 May; 19(1):378. PubMed ID: 31053098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
    Isakov V; Chulanov V; Abdurakhmanov D; Burnevich E; Nurmukhametova E; Kozhevnikova G; Gankina N; Zhuravel S; Romanova S; Hyland RH; Lu S; Svarovskaia ES; McNally J; Brainard DM; Ivashkin V; Morozov V; Bakulin I; Lagging M; Zhdanov K; Weiland O
    Infect Dis (Lond); 2019 Feb; 51(2):131-139. PubMed ID: 30499360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Drug Treats All Genotypes of Chronic HCV.
    Aschenbrenner DS
    Am J Nurs; 2016 Oct; 116(10):27. PubMed ID: 27684768
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
    Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ
    Clin Infect Dis; 2016 Dec; 63(11):1479-1481. PubMed ID: 27553377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
    Schreiber J; McNally J; Chodavarapu K; Svarovskaia E; Moreno C
    Hepatology; 2016 Sep; 64(3):983-5. PubMed ID: 27177605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
    [No Abstract]   [Full Text] [Related]  

  • 36. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia.
    Mogul A; Teixeira E; McAuliffe L; Promrat K; Zullo AR
    Am J Health Syst Pharm; 2020 Mar; 77(6):417-418. PubMed ID: 31930300
    [No Abstract]   [Full Text] [Related]  

  • 39. Overview of hepatitis C infection, molecular biology, and new treatment.
    Rabaan AA; Al-Ahmed SH; Bazzi AM; Alfouzan WA; Alsuliman SA; Aldrazi FA; Haque S
    J Infect Public Health; 2020 May; 13(5):773-783. PubMed ID: 31870632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hepatitis C virus genotype 4 in the DAA era.
    Di Biagio A; Taramasso L; Cenderello G
    Virol J; 2018 Nov; 15(1):180. PubMed ID: 30466446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.